Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own stem cells are collected, preserved, and returned to them.

Trial Details

NCT ID

NCT06207799

Phase

PHASE2

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Elranatamab
Lenalidomide
Plerixafor
Melphalan
Busulfan
G-CSF

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Transplant eligible patients with newly diagnosed multiple myeloma (NDMM).
High-risk multiple myeloma\*
Participants with disease response ≥ PR to induction therapy
Age ≥ 18 and ≤ 75. Non-English-speaking participants are eligible.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →